Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2013

01-03-2013 | Original Paper

Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer

Authors: Tao Wu, Yi Li, Jianguo Lu, Qing Qiao, Guoqiang Bao, Nan Wang, Xianli He, Xilin Du

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

Matrix metalloproteinase-21 (MMP-21) has been shown to enhance tumor invasion and metastasis ability in some solid tumors. In the present study, we investigated the expression of MMP-21 as well as its association with overall survival of gastric cancer patients. MMP-21 expression was investigated in 296 cases of gastric cancer by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of MMP-21 expression with overall survival of patients. MMP-21 expression was proved to be increased in gastric cancer compared with that in normal tissues (P < 0.05). It was also proved MMP-21 expression was associated with tumor invasion, metastasis and TNM stage (P < 0.001). MMP-21 expression was showed to be associated with overall survival of gastric cancer patients for patients with tumor of higher MMP-21 expression tend to have worse overall survival (P < 0.001). Multivariate analysis proved MMP-21 to be an independent prognostic factor for overall survival of gastric cancer patients (P < 0.001). These results suggested the potential role of MMP-21 in progression of human gastric cancer. It might also be a novel molecular marker to predict overall survival of patients with gastric cancer.
Literature
1.
2.
3.
Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12:17–20.PubMed
4.
5.
Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621–30.PubMedCrossRef
6.
Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;30(274):21491–4.CrossRef
7.
Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–49.PubMed
8.
Park HI, Ni J, Gerkema FE, et al. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem. 2000;275:20540–4.PubMedCrossRef
9.
Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am. 2001;10:383–92.PubMed
10.
Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178–93.PubMedCrossRef
11.
Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999;189:300–8.PubMedCrossRef
12.
Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260–70.PubMedCrossRef
13.
Reis ST, Leite KR, Piovesan LF, et al. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer. BMC Urol. 2012;12:18.PubMedCrossRef
14.
Song N, Sung H, Choi JY, et al. Preoperative serum levels of matrix metalloproteinase-2 (MMP-2) and survival of breast cancer among Korean women. Cancer Epidemiol Biomarkers Prev. 2012 Jun 5.
15.
Ng KT, Qi X, Kong KL, et al. Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. Eur J Cancer. 2011;47:2299–305.PubMedCrossRef
16.
Chen R, Cui J, Xu C, et al. The Significance of MMP-9 Over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2011 Jun 17.
17.
Barresi V, Vitarelli E, Tuccari G, et al. MMP-9 expression in meningiomas: a prognostic marker for recurrence risk? J Neurooncol. 2011;102:189–96.PubMedCrossRef
18.
Chen T, Zhu J. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol. 2010;27:1185–91.PubMedCrossRef
19.
Zeng ZS, Huang Y, Cohen AM, et al. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996;14:3133–40.PubMed
20.
Fujimoto D, Hirono Y, Goi T, et al. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res. 2008;28:847–54.PubMed
21.
Partyka R, Gonciarz M, Jałowiecki P, et al. VEGF and metalloproteinase 2 (MMP-2) expression in gastric cancer tissue. Med Sci Monit. 2012; 18: BR130–4.
22.
Noh S, Jung JJ, Jung M, et al. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology. 2011;58:2015–9.PubMedCrossRef
23.
Koskensalo S, Mrena J, Wiksten JP, et al. MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010;31:149–55.PubMedCrossRef
24.
Al-Batran SE, Pauligk C, Wirtz R, et al. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Ann Oncol. 2011 Nov 23.
25.
Yan D, Dai H, Liu JW. Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma. BMC Cancer. 2011;11:151.PubMedCrossRef
26.
Suomela S, Koljonen V, Skoog T, et al. Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in merkel cell carcinoma. Virchows Arch. 2009;455:495–503.PubMedCrossRef
27.
Boyd S, Virolainen S, Pärssinen J, et al. MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. Exp Dermatol. 2009;18:1044–52.PubMedCrossRef
28.
Germani RM, Civantos FJ, Elgart G, et al. Molecular markers of micrometastasis in oral cavity carcinomas. Otolaryngol Head Neck Surg. 2009;141:52–8.PubMedCrossRef
29.
Qiu W, Zhou G, Zhai Y, et al. No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2008;17:2514–8.PubMedCrossRef
30.
Bister V, Skoog T, Virolainen S, et al. Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma. Mod Pathol. 2007;20:1128–40.PubMedCrossRef
31.
Shagisultanova EI, Novikova IA, Sidorenko YS, et al. The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer. Anticancer Res. 2004;24:199–201.PubMed
32.
Ahokas K, Lohi J, Illman SA, et al. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Lab Invest. 2003;83:1887–99.PubMedCrossRef
33.
Wu T, Li Y, Liu X, et al. Identification of high-risk stage II and stage III colorectal cancer by analysis of MMP-21 expression. J Surg Oncol. 2011;104:787–91.PubMedCrossRef
34.
Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125–30.PubMedCrossRef
Metadata
Title
Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer
Authors
Tao Wu
Yi Li
Jianguo Lu
Qing Qiao
Guoqiang Bao
Nan Wang
Xianli He
Xilin Du
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0323-8

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue

Original Paper

Effects of EHD2 interference on migration of esophageal squamous cell carcinoma

Original Paper

Individual predictors of increased serum mesothelin in asbestos-exposed workers

Review Article

Metastatic gastric cancer treatment: a little slow but worthy progress

Original Paper

Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?

Original Paper

The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma

Original Paper

High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits